最新ニュース HealthEquity (NASDAQ:HQY) 株価情報

HEALTHEQUITY INC

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FIVE

STNE

米国株先物が上昇している中で、米国の水曜日に投資家の関心を集めそうな銘柄は以下の通り。

ウィリアムズ・ソノマ、ヘルスエクイティ、水曜日に注目すべき3銘柄

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

BIDU

CWCO

GETY

SAIC

CNNマネーの『恐怖＆貪欲指数』 は市場全体のセンチメントに若干の改善が見られたことを示したが、月曜日と同じく『極度の恐怖』圏のままである。

経済データの好調から株価がプラス350ポイント上昇：投資家の恐れが和らぐも、Greed指数は「極度の恐怖」ゾーンのまま

HealthEquity Inc

HealthEquity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has risen 7.05% since its last report. The company recently reported that it has 6.18 million shares sold short, which is 8.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746716425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HealthEquity has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About HealthEquity?

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 2.22% on an annualized basis producing an average annual return of 12.6%. Currently, HealthEquity has a market capitalization of $7.61 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $339.58 today based on a price of $87.95 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746135029_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

Keybanc analyst Scott Schoenhaus maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Overweight and lowers the price target from $110 to $100.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on HealthEquity, Lowers Price Target to $100

In the last three months, 8 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.5, a high estimate of $125.00, and a low estimate of $94.00. Marking an increase of 0.22%, the current average surpasses the previous average price target of $112.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372848_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $94.00&#x7C;$107.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $115.00&#x7C;$120.00 &#x7C; 
&#x7C;Scott Schoenhaus &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $110.00&#x7C;$120.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Stan Berenshteyn &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $125.00&#x7C;$110.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $120.00&#x7C;$105.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of HealthEquity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into HealthEquity's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Unveiling the Story Behind HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.24%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's ROA stands out, surpassing industry averages. With an impressive ROA of 0.76%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 8 Analysts

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and lowers the price target from $107 to $94.

Goldman Sachs Maintains Neutral on HealthEquity, Lowers Price Target to $94

AMGN

Live On CNBC, Karen Firestone Announces Bought More HealthEquity; Bought Amgen

Last week, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44386926/healthequity-stock-falls-after-reporting-q4-results-revenue-beat-eps-miss-soft-guidance" rel="noreferrer noopener">missing the consensus of 72 cents.</a>
Revenue increased 19% year over year to $311.8 million, beating the&nbsp;consensus of $306.05 million.
The health savings account (HSA) custodian reported adjusted EBITDA of $107.8 million, an increase of 9%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44403476/healthequity-stock-falls-on-weaker-than-expected-outlook-analyst-expects-better-margins-earnings-growth-in-later-2026-and-beyond" rel="noreferrer noopener">HealthEquity&#8217;s Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says</a>
In a note on Tuesday, analyst Gregory Peters writes that all financial institutions are dealing with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">elevated levels of fraud</a>.
HealthEquity stock&#8217;s recent year-to-date underperformance is partly due to its disclosure of fraud against some of its HSA customers and near-term investor concerns about recent management changes. The stock is inexpensive, and the analyst expects management to utilize the share repurchase program to capitalize on the weakness.
Despite reducing estimates for increased fraud-related costs, Raymond James upgraded HealthEquity to Strong Buy from Outperform.
The analyst lowered the price <a target="_blank" href="https://www.benzinga.com/quote/HQY/analyst-ratings" rel="noreferrer noopener">target from $120 to $115</a>.
&#8220;Longer term, we have a favorable outlook on the growing HSA market, HQY&#8217;s ability to gain market share, and HSA cash repricing at higher yields, which should lead to margin expansion and double-digit EPS growth over each of the next two years,&#8221; Raymond James analyst says.
The analyst writes that the stock has been outperforming peers and the market on a YTD basis due in part to some investors&#8217; flight to quality, the growing expectation for federal legislative improvements in the functionality of HSAs, and a reasonably stable interest rate outlook.
Price Action: HQY stock is up 0.75% at $91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44473580/mural-oncologys-ovarian-cancer-combo-drug-trial-disappoints-stock-plunges" target="_blank" rel="noreferrer noopener">Mural Oncology&#8217;s Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

Health Care

General

HealthEquity Earns Stock Upgrade Despite Fraud Concerns

On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>). Avalo&#8217;s lead asset is AVTX-009, an anti-IL-1β mAb <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">targeting inflammatory diseases</a>.
The company initiated a Phase 2 LOTUS trial, which will include approximately 180 adults with hidradenitis suppurativa (HS), to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo. Topline data is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44413131/avalo-reports-2024-financial-results-and-recent-business-updates" rel="noreferrer noopener">expected in 2026</a>.
Avalo continues to evaluate AVTX-009 for additional immune-mediated diseases with plans to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278240/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-" rel="noreferrer noopener">announce a second indication</a>.
Analyst Alex Thompson writes that the following proof-of-concept data in HS from AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) lebrikizumab, an IL-1α/β bispecific success for AVTX-009, is highly de-risked given the strong evidence suggesting that IL-1β blockade represents the key driver of efficacy for Lutikizumab.
In January 2024, AbbVie&#8217;s Phase 2 results showed that adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg every other week or 300 mg weekly achieved higher response rates (59.5% nominal p=0.027 and 48.7%, nominal p=0.197, respectively) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/n36531984/lutikizumab-showed-positive-results-in-a-phase-2-trial-of-adults-with-moderate-to-severe-hidradeni" rel="noreferrer noopener">than placebo (35%)</a>.
Stifel writes that AVTX-009 can achieve comparable efficacy to lutikizumab albeit with the potential for superior dosing (Q4W vs. Q2W), equating to a meaningful minority share within the growing HS market yielding over $2 billion drug in the US alone amid significant strategic interest in the space.
Stifel has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AVTX/analyst-ratings" rel="noreferrer noopener">price target of $36</a>.
&#8220;Bottomline we think AVTX represents an attractive HS pure-play with a favorable risk-reward heading into topline Ph2 data in the 2026 timeframe. Strong external HS newsflow over the next 12 months offers an additional tailwind,&#8221; Stifel analyst writes.
Cash and cash equivalents&nbsp;were $134.5 million as of December 31, 2024. The company&#8217;s current cash on hand is expected to fund operations into at least 2027.
Price Action: AVTX stock is up 15.5% at $8.81 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44473549/pony-ai-q4-revenue-slumps-nearly-30-as-robotaxi-sales-decline-loss-widens" target="_blank" rel="noreferrer noopener">Pony AI Q4: Revenue Slumps Nearly 30% As Robotaxi Sales Decline, Loss Widens</a></li>
</ul>

Biotech

Initiation

Movers

ABBV

AVTX

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Michael Halloran upgraded the rating for Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) from Neutral to Outperform and maintained the price target of $114. Pentair shares closed at $89.85 on Monday. <a href="https://www.benzinga.com/quote/PNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst C. Gregory Peters upgraded HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Outperform to Strong Buy but lowered the price target from $120 to $115. HealthEquity shares closed at $90.32 on Monday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Kevin Yin upgraded MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) from Neutral to Overweight and raised the price target from $15 to $22. MINISO Group shares closed at $18.35 on Monday. <a href="https://www.benzinga.com/quote/MNSO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Madeline Brooks upgraded the rating for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Underperform to Buy and raised the price target from $60 to $160. Cloudflare shares closed at $123.93 on Monday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Adam Jonas upgraded Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) from Equal-Weight to Overweight and boosted the price target from $260 to $280. Carvana shares closed at $213.63 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NET stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44472214/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

CVNA

MNSO

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Raymond James analyst C. Gregory Peters upgrades HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Outperform to Strong Buy and lowers the price target from $120 to $115.

Raymond James Upgrades HealthEquity to Strong Buy, Lowers Price Target to $115

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 2.94% on an annualized basis producing an average annual return of 13.71%. Currently, HealthEquity has a market capitalization of $7.81 billion. 
Buying $1000 In HQY: If an investor had bought $1000 of HQY stock 10 years ago, it would be worth $3,618.59 today based on a price of $90.32 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742851815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

Keybanc analyst Scott Schoenhaus maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Overweight and lowers the price target from $120 to $110.

Keybanc Maintains Overweight on HealthEquity, Lowers Price Target to $110

In the last three months, 4 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for HealthEquity, revealing an average target of $117.25, a high estimate of $125.00, and a low estimate of $112.00. Witnessing a positive shift, the current average has risen by 6.83% from the previous average price target of $109.75.
<img src="https://www.benzinga.com/files/images/story/2025/1742414451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Get to Know HealthEquity Better</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Understanding the Numbers: HealthEquity's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.55% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess HealthEquity: What You Need To Know

On Tuesday, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago, <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44386926/healthequity-stock-falls-after-reporting-q4-results-revenue-beat-eps-miss-soft-guidance" rel="noreferrer noopener">missing the consensus of 72 cents.</a>
Revenue increased 19% year over year to $311.8 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results" rel="noreferrer noopener">consensus of $306.05 million</a>.
The health savings account custodian reported adjusted EBITDA of $107.8 million, an increase of 9%.
Health savings accounts (HSAs) as of January&nbsp;31, 2025, were 9.9&nbsp;million, an increase of 14% year over year, including 753,000 HSAs with investments, an increase of 23% year over year. As of January&nbsp;31, 2025, total accounts were 17.0 million, including 7.1 million other consumer-directed benefits (CDBs).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
Guidance: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion, compared to estimates of $1.301 billion.
The company anticipates adjusted EPS of $3.57 to $3.74, compared to the consensus of $3.71. Management expects Adjusted EBITDA of $525 million to $545 million.
Barrington Research maintains HealthEquity with an <a target="_blank" href="https://www.benzinga.com/quote/HQY/analyst-ratings" rel="noreferrer noopener">Outperform and a $112 price target.</a>
Analyst Alexander Paris writes the earnings were impacted by excess costs associated with cyber-fraud prevention and reimbursements.
&#8220;While the magnitude of the excess costs associated with cybersecurity fraud and prevention was more than expected, we are &#8220;looking over the valley&#8221; to better margins and earnings growth in 2H/26 and beyond,&#8221; analyst Paris writes.
With HQY&#8217;s strong HSA business and higher cash yields expected in the coming years, the analyst writes that the company&#8217;s overall financial and operational performance will keep improving once temporary extra costs subside.
Price Action: HQY stock is down 18.9% at $82.46 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44394046/oracle-integrates-nvidia-ai-enterprise-and-secures-major-defense-cloud-deal-with-singapore" target="_blank" rel="noreferrer noopener">Oracle Integrates NVIDIA AI Enterprise and Secures Major Defense Cloud Deal with Singapore</a></li>
</ul>
Image via Shutterstock.

Equities

Guidance

Reiteration

HealthEquity's Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

OABI

SCNX

TNXP

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 200 points on Wednesday.
The Dow traded up 0.55% to 41,808.59 while the NASDAQ climbed 0.95% to 17,671.26. The S&amp;P 500 also rose, gaining, 0.66% to 5,651.61.
Check This Out: <a href="https://www.benzinga.com/25/03/44396179/how-to-earn-500-a-month-from-jabil-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Jabil Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 1.2% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.7%.
Top Headline
The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Service Properties Trust &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NASDAQ">SVC</a>) shares shot up 18% to $2.94 after Wells Fargo upgraded the stock from Underweight to Overweight and raised its price target from $2.5 to $4.</li>
<li>Shares of Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>)got a boost, surging 31% to $2.7640 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>BGM Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) shares were also up, gaining 16% to $11.79 after the company announced the acquisition of YX for $95 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares dropped 18% to $83.35 after the company reported worse-than-expected fourth-quarter adjusted EPS results.</li>
<li>Shares of Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) were down 30% to $0.2815 after the company announced a 1-for-12 reverse stock split.</li>
<li>OmniAb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) was down, falling 17% to $2.6545 following fourth-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $67.38 while gold traded down 0.1% at $3,040.50.
Silver traded down 1.6% to $34.275 on Wednesday, while copper rose 1.2% to $5.0765.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.12%, Germany's DAX 40 fell 0.55% and France's CAC 40 gained 0.65%. Spain's IBEX 35 Index rose 0.30%, while London's FTSE 100 rose 0.08%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index falling 0.1%, Hong Kong's Hang Seng Index gaining 0.12% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>U.S. mortgage applications declined by 6.2% in the second week of March, following a cumulative 37% increase from the two prior weeks.</li>
<li>The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>

Eurozone

Commodities

Intraday Update

ATER

ONVO

Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ABSI/earnings">worse-than-expected fourth-quarter financial results.</a>
Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported quarterly sales of $665.000 thousand which missed the analyst consensus estimate of $1.778 million.
Absci shares dipped 9.4% to $2.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares dipped 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares fell 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) declined 6.5% to $1.30 in pre-market trading following a 5% fall on Tuesday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) declined 4.3% to $34.53 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) fell 3.8% to $5.63 in pre-market trading.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) fell 3.2% to $31.47 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>
Photo: Shutterstock

ABSI

ATGL

RHLD

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 45.4% to $2.93 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 32.73% to $2.23. The company's market cap stands at $126.3 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares moved upwards by 22.55% to $2.88. The market value of their outstanding shares is at $113.4 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock rose 18.68% to $4.51. The market value of their outstanding shares is at $207.6 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock moved upwards by 17.58% to $1.07. The market value of their outstanding shares is at $16.4 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock increased by 12.41% to $0.65. The company's market cap stands at $18.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 19.9% to $0.36 during Wednesday's pre-market session. The company's market cap stands at $22.2 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock decreased by 18.52% to $2.86. The market value of their outstanding shares is at $386.7 million. </li>
<li>Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) shares decreased by 16.13% to $15.76. The market value of their outstanding shares is at $2.6 billion. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined by 15.61% to $85.8. The company's market cap stands at $7.4 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 14.88% to $26.9. The company's market cap stands at $350.0 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares fell 12.85% to $1.56. The market value of their outstanding shares is at $30.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

CRGX

IMVT

INNV

NXTC

OSRH

PASG

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Legal

Press Releases

If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY

USA Today Names HealthEquity to its Top 25 Workplaces

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HealthEquity, Inc. - HQY

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Keybanc

Barrington Research

Goldman Sachs

Raymond James

Wells Fargo

米国株先物が上昇している中で、米国の水曜日に投資家の関心を集めそうな銘柄は以下の通り。
<ul>
<li>ウォール街の情報筋によると、株式市場開場前にシグネット・ジュエラーズ(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>)は純利益1株6.25ドル、総収入233億ドルの決算発表の見通し。</li>
<li>アナリストは、ウィリアムズ・ソノマ(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)が純利益1株2.93ドル、総収入235億ドルで四半期決算を発表すると予想。同社は本日、市場が開く前に決算発表の予定。ウィリアムズ・ソノマの火曜日の終値は1.6％安の172.28ドル。</li>
<li>火曜日、ヘルスエクイティ(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)は四半期決算を業績不振と発表。ヘルスエクイティは2026会計年度の売上高を12億ドルから13.05億ドルの範囲であると見込んでいるが、市場予想は13.01億ドル。同社は1株あたりの通年収益を1株あたり、3.57ドルから3.74ドルになると予想しているが、市場予想は1株あたり3.71ドル。ヘルスエクイティの株価は、時間外取引で13.7％下落し、87.75ドル。</li>
</ul>
［<a href="https://www.benzinga.com/premarket/">今日のプレマーケットをチェック</a> ］
<ul>
<li>ストーンコー(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>)は、第4四半期の決算および売上高が予想を上回る結果を発表。時間外取引でのストーンコーの株価は10.2％高の10.85ドル。</li>
<li>アナリストは、ファイブ・ビロウ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)の決算発表は、1株あたり3.38ドルの純利益、総収入13.9億ドルになると予想。ファイブ・ビロウの時間外取引での株価は、1.3％上昇し、74.88ドル。</li>
</ul>
　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　以上

CNNマネーの『恐怖＆貪欲指数』 は市場全体のセンチメントに若干の改善が見られたことを示したが、月曜日と同じく『極度の恐怖』圏のままである。
月曜日に上昇したにもかかわらず、米国株式は先週は下落した。ダウ平均株価は約3.1%下落し、2023年3月以来最悪の週となった。主要３指数はいずれも、前回の取引に続く上昇を記録しました。S&amp;P 500は2%以上下落し、4週連続のマイナスとなった。
ゲス ？(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) の株は、WHP Global社から1株あたり現金13ドルでの買収提案があったと発表した後、30％急騰した。 バイドゥ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) の株は、同社がERNIE 4.5と深層思考モデルERNIE X1の提供を発表した後、9％上昇した。
経済指標では、2月の米国小売売上高は前月比0.2％増、前月は1.2％減（改定値）となり市場予想の0.6％増を下回った。また、３月のNYエンパイアステート製造業景況指数は26ポイント減の-20.0を記録し、2023年5月以来の最低値になった。３月のNAHB /ウェルズファーゴ住宅市場指数は39に下がり、先月の42からの下落した。
S&amp;P500のセクターについては、不動産、エネルギー、日用消費品の株が、先週末に上昇した。一方で、日用品の株は週明けの取引で下落した。
月曜日、ダウは約353ポイント上昇し、41,841.63ドルで引けた。S&amp;P500は0.64％上昇し5,675.12ドル、ナスダック総合指数も0.31％上昇し17,808.66ドルで引けました。
本日の投資家たちが注目しているのは、IHS ホールディングス(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) 、 ヘルスエクイティ(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) 、 ストーン (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) の決算発表です。
『CNNビジネス 恐怖＆貪欲指数』とは？
『恐怖＆貪欲指数』の現在22.1、先週は20.9、先週月曜日から『極度の恐怖』のままである。
この 恐怖＆貪欲指数とは、現在の市場センチメントを測定する。この指数は、恐怖心が高まると株価に圧力がかかり、一方で欲望が高まるとその逆の影響が出る。この指数は7つの同じ比重を持つ指標に基づいて計算される。この指数は0から100の間の値を取り、０が最大の恐怖を示し、100が最大の欲望を示す。
p&gt; 次の一手: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">ジム・クレイマーが「ミーム株」と呼んだ銘柄とは？アクセンチュアの株を購入することを推奨</a></li>
</ul>
写真提供:シャッターストック

Comments

HealthEquity

ニュース

最新ニュース HealthEquity (NASDAQ:HQY) 株価情報

水曜日, 3 19, 2025

火曜日, 3 18, 2025

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル